News

Neogen Corp Investors Alerted: Class Action Lawsuit Updates

Neogen Corp Investors Alerted: Class Action Lawsuit Updates

Neogen Corporation Class Action Alert

Investors in Neogen Corporation have received a timely reminder regarding an important deadline associated with a securities class action lawsuit. Those who have incurred losses exceeding $100,000 during the designated period are eligible to take part in this legal action, making it crucial for them to stay informed about their rights and the next steps involved.

Details of the Securities Class Action

The class action lawsuit against Neogen Corporation centers on allegations that the company, along with certain executives, failed to disclose crucial information that is material to investors during the class period. Specifically, shareholders who purchased Neogen shares from January 5, 2023, through June 3, 2025, are directly impacted. The claim is currently filed in the United States District Court for the Western District of Michigan.

What You Need to Know

Investors aiming to participate must file their applications for lead plaintiff status by the upcoming deadline. This is a protective measure intended for shareholders to ensure they can advocate for their interests in the class action case effectively. The timeline set for this class action is crucial and demands immediate attention from those who might qualify.

Recent Developments Impacting Neogen's Share Value

Recent financial disclosures by Neogen have raised significant concerns among investors. On one notable occasion, the company reported a 3.4% decline in quarterly revenue, amounting to $221 million. This downturn was largely attributed to unforeseen integration issues, leading to a downward revision of their financial guidance for FY25. Included in the announcement was the expected capital expenditure of $100 million due to lower adjusted EBITDA.

Market Reaction and Stock Performance

The reaction from the market was swift—as soon as this information was made public, Neogen's stock experienced steep declines. For instance, on April 9, 2025, the price of Neogen shares fell by 28%, closing at $5.02 per share amid heightened trading activity. Furthermore, a subsequent announcement regarding expected EBITDA margins also contributed to ongoing declines, as shares fell further to $4.96 shortly thereafter.

Legal Options for Affected Investors

For those affected by the declines in share value, seeking legal recourse through this class action could prove beneficial. Law firms, such as Kahn Swick & Foti, LLC, are available to offer consultations for investors wanting to explore their options for participating in the class action lawsuit and potentially recovering losses incurred during the troubled financial period.

Next Steps for Neogen Investors

Investors are encouraged to act promptly and gather all necessary documentation regarding their shares in Neogen. By submitting their lead plaintiff applications ahead of the deadline, they can ensure their voices are heard in this crucial legal battle. For further support, it is advisable to reach out to ClaimsFiler, a dedicated resource helping retail investors navigate the complexities of class action settlements.

Frequently Asked Questions

What is the lead plaintiff deadline for the class action against Neogen?

The lead plaintiff deadline for the class action lawsuit against Neogen Corporation is set for September 16, 2025.

How can I determine if I'm eligible for the class action?

If you purchased shares of Neogen between January 5, 2023, and June 3, 2025, you may be eligible to participate in the class action.

What factors led to the decline in Neogen's stock value?

The decline in Neogen’s stock value can be attributed to integration issues, lowered revenue forecasts, and diminished EBITDA margin expectations.

What should I do if I incurred losses from Neogen shares?

If you incurred losses, consider consulting with a law firm experienced in securities class actions to discuss your legal options.

Who can I contact for more information about my rights?

Investors seeking information on their rights can contact ClaimsFiler at toll-free (844) 367-9658 or visit their website for further assistance.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Valmet Expands Board Maker Deal in Asia With New Line

Updated Category News Views 87

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

Continue Reading
O-I Glass Faces Class Action: Investor Implications

Updated Category News Views 68

O-I Glass in Hot Water Over Misleading Statements I'll tell you, nothing gets my goat quite like uncovering deceptive practices in the corporate world. It seems O-I Glass, Inc. (NYSE: OI), might have played a fast one with its shareholders. The company is staring down the barrel of a class action lawsuit from Schall, Brown & Schwartz LLP, alleging they weren't entirely...

Continue Reading
KT&G Launches Heated Tobacco in Kazakhstan's Market

Updated Category News Views 43

KT&G Lights Up Kazakhstan In a bold move, KT&G is laying down the gauntlet in Kazakhstan's tobacco market, introducing its cutting-edge heated tobacco gizmo and a handful of sleek FAIIM sticks. Launching this October, these aren't just any devices—they're the FLEX locals have been waiting for, rebranded from South Korea's lil AIBLE and AIIM but made to fit right in with...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 178

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 730

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 323

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 226

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
Niagara Networks Boosts TLS 1.3 Decryption to 90+ Gbps

Updated Category News Views 73

In a digital era where encryption is racing ahead like a runaway train, Niagara Networks has stepped up with some serious muscle enhancements to their ePacketron platform. They're not just playing catch-up with the latest TLS 1.3 decryption capabilities; they're leading the charge with a robust over 90 Gbps performance—no small feat in today's encrypted traffic...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 490

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 228

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
aria-label="Continue reading: JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer"> Continue Reading